The bicyclam AMD3100 story
Top Cited Papers
- 1 July 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 2 (7), 581-587
- https://doi.org/10.1038/nrd1134
Abstract
The discovery and development of the bicyclam AMD3100--a chemokine receptor antagonist--has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.Keywords
This publication has 39 references indexed in Scilit:
- The therapeutic potential of CXCR4 antagonists in the treatment of HIVExpert Opinion on Investigational Drugs, 2003
- AMD3100, a CxCR4 Antagonist, Attenuates Allergic Lung Inflammation and Airway HyperreactivityThe American Journal of Pathology, 2002
- Safe Use of the CXCR4 Inhibitor ALX40-4C in HumansAIDS Research and Human Retroviruses, 2001
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998
- Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4The Journal of Experimental Medicine, 1997
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996
- Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1Antiviral Research, 1996
- The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after bindingAntiviral Research, 1996
- ANTIMONIOTUNGSTATE (HPA 23) TREATMENT OF THREE PATIENTS WITH AIDS AND ONE WITH PRODROMEThe Lancet, 1985